Recent work has implicated the Lateral Habenula (LHb) in the production of anxiogenic and aversive states. It is innervated by all the major monoamine neurotransmitter systems and has projections that have been shown to modulate the activity of both dopaminergic and serotonergic brain regions. Cocaine is a stimulant drug of abuse that potentiates neurotransmission in these monoamine systems and recent research suggests that the drug's behavioral effects may be related in part to its actions within the LHb. The present research was therefore devised to test the hypothesis that alterations in serotonin (5-HT) function within the LHb can affect the behavioral response to cocaine. Male rats were fitted with intracranial guide cannula and trained to traverse a straight alleyway once a day for a 1 mg/kg i.v. injection of cocaine. Intra-LHb pretreatment with the 5-HT 1B agonist CP 94,253 (0, 0.1, or 0.25 μg/side) attenuated the development of approach/avoidance "retreat" behaviors known to be a consequence of cocaine's dual rewarding (approach) and anxiogenic (avoidance) properties. This effect was reversed by co-administration of a selective 5-HT 1B antagonist, NAS-181 (0.1 μg/side), demonstrating drug specificity at the 5-HT 1B receptor. These data suggest that 5-HT 1B signaling within the LHb contributes to the anxiogenic effects of cocaine.
Introduction
Cocaine has long been known to produce both an initial euphoric "high" followed by an aversive "crash" characterized by dysphoria, irritability, anxiety, and cravings [1] [2] [3] . This pattern of the rewarding and aversive effects of cocaine fits well with Solomon & Corbit's "Opponent Process Theory" of motivated behavior [4] , where an initial shift in affect (either positive or negative) is followed by a delayed opponent process that serves to return the organism to affective homeostasis. The actions of cocaine closely adhere to this theory, in that while the initial effects of the drug are rewarding, this positive state is followed in time by a strong aversive/anxiogenic state [5] . So, for example, animals develop preferences for distinct places paired with the immediate effects of the drug, but come to avoid places associated with the drug effects present 15-min after an i.v. injection [6] [7] [8] [9] . Koob and others, have suggested that one of the primary features of drug addiction involves a dysregulation of these homeostatic processes whereby tolerance builds to the initial rewarding effects of the drug while the delayed negative effects become sensitized [10] [11] [12] [13] [14] [15] .
The Lateral Habenula (LHb) has recently been implicated in mediating both rewarding and aversive states [16] [17] [18] . Electrophysiological studies of the LHb suggest a role for this region in preventing or blocking the behavioral impact of rewarding stimuli via an inhibition of midbrain substantia nigra dopamine (DA) "reward" neurons [19, 20] . Neuroimaging studies in humans have likewise shown that the LHb appears to be selectively activated by aversive stimuli [21, 22] . Many of the recent studies of the habenula have focused on its ability to regulate DA release [23, 24] . However, it has long been known that the LHb has prominent reciprocal projections to both the Dorsal (DRN) and Median (MRN) Raphé nuclei of the brainstem [25] [26] [27] . More recent anatomical investigations of this region have revealed that it is the medial portions of the LHb that receive direct serotonergic innervation that in turn send projections to acetylcholine-(ACh), DA-and serotonin-(5-HT) releasing cells of the midbrain and hindbrain. The more lateral portion of the LHb directs its output towards the rostromedial tegmental nucleus (RMTg), a GABA-ergic cell group that exerts inhibition upon both the DA cells of the ventral tegmental area (VTA), as well as on serotonergic cells located in both the dorsal and median raphé nuclei [27] . Thus, the LHb is in a prime position to regulate the brain serotoninergic system through both direct and indirect pathways.
Given that 5-HT has been strongly linked to the development and expression of anxiety-like behavior [28] [29] [30] , coupled with the fact that cocaine is known to elevate synaptic 5-HT through inhibition of the serotonin transporter (SERT) [31] [32] [33] [34] suggests a putative role for 5-HT in the aversive behavioral response to cocaine. Consistent with this hypothesis are prior studies from our own laboratory demonstrating that inactivation of 5-HT cell bodies in the DRN [35] and systemic treatment with the 5-HT 1A partial agonist, buspirone [36] , reduced the development of approach/avoidance "retreat" behavior in a runway model of drug self-administration. Buspirone was also effective at selectively diminishing the delayed aversive effects of the drug, while leaving the initial positive effects intact as measured in tests of place conditioning [37] .
The LHb expresses a variety of 5-HT receptors, including the 5-HT 1 , 5-HT 2 , 5-HT 3 , 5-HT 5 , and 5-HT 7 families [27] . Of particular interest to the current study was the presence of inhibitory 5-HT 1B receptors in the LHb [38] [39] [40] . The 5-HT 1B receptor is an inhibitory Gi-coupled receptor that is primarily located on axon terminals as an auto-or hetero-receptor [41] . Additionally, systemic treatment with 5-HT 1B agonists has been shown to produce anxiolytic-like effects across multiple behavioral tests [42, 43] , which further supports the hypothesis that this receptor may modulate the anxiogenic response to cocaine. Thus, the present study was designed to investigate the role of 5-HT signaling in the LHb via manipulation of 5-HT 1B receptors on the development of the anxiogenic effects of self-administered cocaine.
Methods

Subjects
The subjects were 122 male Sprague-Dawley rats (Charles River Labs, Hollister, CA) weighing approximately 300 g at the time of surgery. Rats were pair-housed within a temperature-controlled (22°C) vivarium maintained on a reverse 12-h light/dark cycle (lights on at 20:00 h) and had ad libitum access to both food (Purina rat chow) and water. Animals were handled daily for at least 7 days prior to surgery. All methods were conducted in strict adherence to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the UCSB Institutional Animal Care and Use Committee.
Surgery
As previously described [44] , each subject was deeply anesthetized with an intramuscular injection of ketamine and xylazine (56.25 and 7.5 mg/kg, respectively; Abbott Laboratories) and fitted with an indwelling intravenous (i.v.) catheter (13 mm of microrenathane tubing, 0.014 mm inner diameter, 0.33 mm outer diameter; Braintree Scientific) inserted into the right jugular vein, secured in place by silk sutures, and subcutaneously (s.c.) passed to a threaded guide cannula (catalog #313G; Plastics One) that exited though a 2 mm hole on the animal's back. The guide cannula was cemented to a 3 cm square piece of Mersiline mesh (Bard) that was laid flat subcutaneously on the animal's back where it was secured with surgical glue. While still anesthetized, each rat was then fitted with bilateral intracranial guide cannulae (22 gauge, 9 mm; Catalog #313GA/SPC; Plastics One) stereotaxically aimed 1 mm above the LHb using the following coordinates relative to bregma: AP −3.4, ML ± 1.5, and DV −3.2 from skull surface with a lateral inclination of 11° [45] . During surgery, subjects received the non-opiate analgesic meloxicam (2 mg/kg s.c. at a concentration of 5 mg/ml in saline) to control for post-surgical pain in addition to Buprenorphine HCl (0.05 mg/kg, 0.3 mg/ml), and saline for rehydration (3.0 ml s.c.). The catheters were flushed with the antibiotics cefazolin + gentamycin (0.25 ml of 1 mg/ml & 5 mg/ml, respectively) to prevent infection and heparinized saline (6.25 IU, 0.1 ml i.v.) to retain patency.
After surgery, catheter patency was maintained via daily flushing with 0.1 ml cefazolin and gentamycin (1 mg/ml & 5 mg/ml, respectively) followed by 0.1 ml of heparinized 0.9% physiological saline.
Animals were allowed to recover for at least 7 days prior to behavioral testing. Catheter patency was periodically assessed through observation of the loss of the righting reflex following an i.v. injection of the fastacting barbiturate, methohexital (Brevital, 2.0 mg/kg/0.1 ml). Rats that were unresponsive to Brevital prior to the start of behavioral testing were re-implanted with a new catheter using the left jugular vein and given additional days for recovery. Catheter patency failure during the course of behavioral testing resulted in subject removal from data analysis.
Drugs
Cocaine hydrochloride (provided by the National Institute on Drug Abuse) was dissolved in 0.9% physiological saline and sterile filtered through a 0.22 μm filter (ThermoScientific). Cocaine was diluted to a dose of 1 mg/kg delivered in a volume of 0.1 ml over a period of 4.6 s via a 10 ml syringe nested in a motorized syringe pump (Razel Scientific Instruments). The dose of 1 mg/kg i.v. cocaine was chosen based upon the results of previous runway work from our laboratory [5, 9, 36, 46, 47] .
The 5-HT 1B agonist CP 94,253 dihydrochloride (Sigma-Aldrich) was prepared in a vehicle solution of aCSF (L-ascorbic acid 0.35 g/l, NaCl 8.47 g/l, KCl 0.20 g/l, MgCl2 0.20 g/l, CaCl2 0.18 g/l, NaH2PO4 0.276 g/l, Na2HPO4 0.5362 g/l) for intracranial infusion at the concentrations of 0.1 or 0.25 μg/0.5 μl. In Experiment II, the 5-HT 1B antagonist NAS-181 was prepared in the same vehicle as CP 94,253 and co-infused at a dose of 0.1 μg/0.5 μl/side. The drug CP 94,253 was selected because it shows the greatest affinity for 5-HT 1B over other receptors in the 5-HT 1 family [48] , and has produced behavioral effects in prior studies using intracranial administration at comparable doses [49, 50] . The drug NAS-181 was selected due to its high affinity for the 5-HT 1B receptor and ability to block agonist binding [51] [52] [53] . Previous work from our laboratory has shown that 0.1 μg of NAS-181 is sufficient to reverse the behavioral effects of an even higher dose of CP 94,253 than was used in the present study [44] .
Apparatus
Experimental testing was conducted in two identical wooden straight-arm runways. Each apparatus measured 155 cm (L) × 15 cm (W) × 40 cm (H). On opposite ends of the straight alley were identically sized start and goal boxes (each measuring 24 cm × 25 cm × 40 cm) each separated from the middle runway section of the apparatus by retractable doors. Along the interior length of the alley were 13 infrared photodetector-emitter pairs positioned in the walls 16 cm apart from one another. Input from these photocells was fed through an Any-Maze interface (Stoetling) to a laptop computer running Any-Maze software, which recorded the subjects' locations in the runway in real time throughout each trial. For a more detailed description of the runway apparatus and drug delivery system see Geist and Ettenberg [54] .
Procedures
Prior to the first cocaine-reinforced trial, subjects were individually placed into the start box and permitted to freely explore the runway for 10 min to allow for acclimation to the apparatus (the goal door remained closed to prevent entry into the goal box). The first of 16 single daily runway trials began the following day.
The subjects were administered bilateral intra-LHb infusions (0.5 μl/side) of one of two doses of CP 94,253 (0.1 or 0.25 μg/side (Experiment I), or the combination of 0.25 μg CP 94,253 with 0.1 μg NAS-181 per side (Experiment II), or vehicle prior to each runway trial. The infusions were administered slowly over 120 s using a 25 μl Hamilton syringe that was seated in a motorized syringe pump (KD Scientific). The syringe was connected via PE20 tubing to 28-gauge internal cannula (catalog #313LI/SPC Plastics One) that, when inserted into the implanted intracranial guide cannula, projected 2 mm beyond the tip of the guide cannula. The internal cannula were left in place for 60 s following each infusion to permit diffusion of the drug away from the injection tip. After 10 min, each subject was moved to the runway apparatus, connected to the i.v. drug delivery system, and placed into the start box where, after 5 s, the start door was opened and the trial initiated. Animals were free to traverse the runway until they entered the goal box at which point the goal door automatically closed behind them (to prevent retracing) and an i.v. infusion of 1.0 mg/kg cocaine (in 0.1 ml) was administered over 4.6 s. After 5 min, the subjects were removed from the goal box, disconnected from the drug delivery system, and returned to their home cages. On the rare occasion that an animal did not enter the goal box within 10 min, it was gently encouraged (pushed from behind) to enter the goal box, where it then received an i.v. injection of cocaine. All trials for a given subject were conducted in the same apparatus. To maintain catheter patency, animals were flushed with 0.1 ml of cefazolin/gentamycin followed by 0.1 ml heparinized saline after removal from the apparatus.
Spontaneous locomotor activity
To ensure that central application of the intra-LHb infusions did not produce nonspecific alterations in the response capacity of the subjects, they were examined in a test of spontaneous locomotor activity following completion of runway testing. Locomotor behavior (total distance traveled) was measured in 12 identical Plexiglas chambers each measuring 20 cm (L) × 40 cm (W) × 20 cm (H) (Kinder Scientific). Each test chamber was equipped with an array of fifteen infrared photodetector-emitter pairs evenly spaced along its long axis and seven along its narrow axis, all 8 cm above the floor surface. Movement within the chamber produced photobeam interruptions that were recorded by a desktop computer running Motor Monitor software (Kinder Scientific). At the start of testing, all animals were allowed to acclimate to the locomotor chambers for 60 min. Rats were then removed from the test chambers, administered the same bilateral microinjections that they had received previously during runway testing, and immediately returned to the locomotor chambers for an additional 15-min test session.
Histology
After completion of behavioral testing, animals were euthanized with an overdose of sodium pentobarbital and phenytoin sodium solution (Euthasol; Virbac) and perfused through the heart with 120 ml phosphate-buffered saline (PBS) followed by 120 ml 4% paraformaldehyde (PFA) in PBS. Brains were removed and post-fixed in 4% PFA, after which cannula placements were determined from Nisslstained 40 μm frozen coronal sections. Fig. 1 shows the placement of bilateral cannula tips located in the targeted region (figure adapted from the brain atlas of Paxinos and Watson [28] ). Inclusion of subjects in the experiment required strict histological confirmation that both cannula tips were accurately localized to the LHb. Any animal with microinjector tips located outside the target region or displaying significant necrosis around injector tips was removed from the study (n = 23). The final histological determination of a subject's inclusion in the study was made by an individual blind to that animal's treatment group (AE). An additional 30 animals failed to maintain catheter patency throughout the duration of the study and were similarly removed from the data analysis resulting in a final total sample size of 69 subjects for analysis.
Results
Histology
Experiment I: intra-LHb infusion of CP 94,253
This experiment tested the effects of bilateral intra-LHb microinjections of CP 94,253 (0, 0.1, or 0.25 μg/0.5 μl/side) on the runway behavior of animals approaching and entering a goal box associated with the administration of 1.0 mg/kg i.v. cocaine. Group sizes were N = 22, 13, 18, respectively. Fig. 2 depicts the mean (+SEM) runway performance of the 3 groups of animals during the 16 days of runway testing. A two-factor (Group × Trials) Analysis of Variance (ANOVA) conducted on the start latency data revealed a significant main effect of Trial F(15,750) = 6.822, p < .001, but no main effect of Group and no Group × Trial interaction (p's > .05). Thus, all animals, irrespective of group, learned the association between the goal box and drug delivery and displayed an increasing motivation to seek the drug (faster start times) as testing progressed. However, despite the fast start latencies, animals took longer and longer to enter the goal box. Another twofactor (Group × Trial) ANOVA computed on the run time data confirmed a significant main effect of Trial (F(15,750) = 2.876, p < .001) but in the opposite direction of start times (see middle panel of Fig. 2) . While there was no main effect of Group (F(2,50) = 2.298, p = .111), there was a statistically significant Group x Trial interaction (F (30,750) = 1.641, p = .017), reflecting the fact that on the early trials of testing the Groups performed comparably while by the end of testing the run times of the three groups diverged. A series of pairwise comparisons computed on these data revealed a significant group difference between animals treated with vehicle versus the 0.25 μg dose (p = .038). To confirm this assessment, the mean Run Times for the three groups were recomputed by averaging performance during the first 8 trials to that observed during the final 8 trials. Those results are depicted in Fig. 3A . A two-factor (Group × Trials) ANOVA computed on these data produced results consistent with the ANOVA computed on all trials. There was no main effect of Trials (F(1,50) = 0.185, p = .669), or Group (F(2,50) = 2.298, p = .111), however there was a significant Group × Trials interaction (F(2,50) = 3.982, p = .025). To elucidate the source of this interaction, a one-way ANOVA was computed on the data for each set of trials, which revealed no group differences during trials 1-8 (F(2,52) = 0.373, p = .691), but a significant effect of Group during trials 9-16 (F(2,52) = 4.778, p = .013). Post hoc analysis by LSD testing showed that the 0.25 μg dose was significantly different than vehicle-treated animals (p = .003). The increase in Run Times observed as testing progressed was mirrored by the frequency of approach-avoidance retreat behaviors (see Figs. 2 and 3B) . Not surprisingly, an animal that stops and retreats back toward the start box will necessarily delay its entry into the goal box. This was confirmed via Pearson correlational analyses, whereby each animal's run time was correlated with the frequency of approachavoidance retreats during each of the 16 days of testing. Unsurprisingly, the correlation between run times and retreats was statistically significant on all 16 days of testing (Table 1) .
A two-factor (Group × Trials) ANOVA was computed on the approach-avoidance retreat data (Fig. 2, bottom panel) , which revealed a was done for the run time analysis, the data was analyzed by comparing performance over the first half of trials versus the last half of trials. The results were comparable to those observed for run times. A two-factor (Group × Trials) ANOVA was computed on the data collapsed across trials. This analysis revealed a significant main effect of Trials (F (1,50) = 30.742, p < .001), no main effect of Group (F(2,50) = 1.909, p = .159), and a significant Group × Trials interaction (F (2,50) = 4.891, p = .011). As was the case for Run Times, a one-way ANOVA comparing group behavior over the first half of trials produced no reliable differences (F(2,52) = .233, p = .793), while a significant group effect was identified during the second half of runway trials (F (2,52) = 3.260, p = .047). Post hoc analysis via LSD testing showed a significant difference between the 0.25 μg dose group and vehicle (p = .014). Indeed, as Fig. 3B illustrates, while retreats increased during the second half of the experiment in the vehicle group (as we have seen previously; e.g. see review by Ettenberg [5] ), intra-LHb pretreatment with the 5-HT 1B agonist CP 94,253 dose-dependently reversed this effect.
Experiment I: locomotor activity
The effects of CP 94,253 on spontaneous locomotor activity was assessed by a two-factor (Group × Time) ANOVA computed on data acquired for 15 min following drug infusion (depicted in Fig. 4 ). Although there was an expected reduction in locomotor activity over time as animals habituated to the apparatus (significant main effect of Time: F(2,86) = 165.85, p < .001), there was no main effect of Group (F (2,43) = 1.315, p = .279) and no Group × Time interaction (F (4,86) = .442, p = .778). Thus, manipulation of the 5-HT 1B receptor in the LHb produced no perceptible alterations in the spontaneous ambulatory behavior of subjects relative to vehicle control.
Experiment II: co-administration of 5-HT 1B agonist and antagonist
To demonstrate specificity to the 5-HT 1B receptor subtype, the effective dose of 0.25 μg CP 94,253 was challenged by co-administration of the highly selective 5-HT 1B receptor antagonist, NAS-181 (0.1 μg/ side; N = 16). NAS-181 was effective at reversing the effect of the agonist on approach-avoidance retreat behavior when co-administered with 0.25 μg of CP 94,253 (Fig. 5) . As in the previous experiment, data for this group was collapsed into the first half and second half of runway trials, and then analyzed by a paired sample two-tailed t-test, which revealed a significant difference in retreat behavior over the course of trials (t(15) = −2.503, p = .024). Indeed, these animals behaved much like the vehicle-treated subjects in Experiment 1 (Fig. 3B) and increased the number of retreats as testing progressed. A direct comparison between the retreat behavior of Vehicle-treated animals from Experiment I on Trials 9-16 and the animals in Experiment II from the same time period showed no differences between the groups (t (36) = 1.207, p = .235). The antagonist, therefore, reversed the retreat-suppressing effects of the 5-HT 1B agonist alone. Additionally, in a subsequent locomotor test, treatment with CP 94,253 + NAS-181 produced no reliable changes (compared to the agonist alone) in locomotor behavior (data not shown).
Discussion
The present study examined the impact of 5-HT 1B receptor stimulation in the LHb on the behavior of animals running a straight alley for i.v. cocaine reinforcement. This work builds upon an extensive body of work in our laboratory which shows that cocaine-reinforced animals develop a characteristic pattern of approach-avoidance retreat behavior that reflects the conflict of entering a location in which subjects had formed mixed positive and negative associations [5, 6, 46] , and which has been replicated by others [8] . Treatment with a selective 5-HT 1B agonist into the LHb produced a dose-dependent decrease in the frequency of retreat behaviors, an effect that was reversed by co-administration with a selective 5-HT 1B antagonist.
These results cannot be easily accounted for by some form of nonspecific motoric effects of the treatment, since neither treatment protocol produced alterations in the spontaneous locomotor activity of subjects. Alternatively, one might argue that the observed reductions in retreat behavior produced by the 5-HT 1B agonist do not stem from a treatment-induced decrease in the drug's aversive effects, but rather an increase in the rewarding properties of cocaine. For example, Parsons et al. [55] reported that systemic or intra-ventricular administration of 5-HT 1B agonists produced changes in cocaine self-administration that mirrored what is seen when the unit dose of cocaine is increased [55] . It has also been suggested that 5-HT 1B receptors present on the GABAergic interneurons of the VTA could lead to a disinhibition of dopamine release, which would be consistent with an enhancement of cocaine reward [56, 57] . It is of course entirely possible that the same drug, when applied to different brain regions, produces region-specific alterations in the activity of different neurotransmitter systems. To turn the argument on its head, the putative enhancement in cocaine reward observed by Parsons et al. [55] could have been due to either a potentiation of the dopaminergic reward signal from the VTA, or alternatively from a reduction in the drug's aversive effects via the LHb, leading to a net increase in reward. Indeed, when a 5-HT 1B agonist is administered systemically, it would be difficult to tease apart potentially opposing actions stemming from drug effects in different brain regions. Additionally, in the current study, we note that CP 94,253 had no effect on subjects' start latencies, a measure reflective of the positive incentive properties of goal box stimuli (such as cocaine) [5] . When taken together, the current findings are therefore consistent with the hypothesis that the observed reductions in approach-avoidance retreat behaviors were due, not to an elevation in the rewarding properties of cocaine, but rather to a reduction in the drug's negative/anxiogenic effects.
There is ample evidence demonstrating an intimate inverse relationship between the VTA and LHb. Early studies investigating the relationship between these two regions found that stimulation of the LHb produces an inhibition of VTA DA cell firing [58] . It was later shown by Matsumoto and Hikosaka [19] that this circuit is responsible for encoding an "anti-reward" signal. Their experiments elegantly showed how the LHb responds to both negative outcomes, as well as the lack of an expected reward, by an increase in its own activity while simultaneously inhibiting the VTA. Likewise, the rewarding conditions that produced strong activations of VTA DA cells also inhibited the activity of LHb neurons [19] . In later research, these projections from the LHb were found to be glutamatergic and inhibitory to the VTA via activation of GABAergic cells of the RMTg [59, 60] . Additionally, the reverse pathway has also been identified using optogenetic methods-a population of presumptively GABAergic VTA neurons that inhibit the LHb and promote reward [61] . Jhou et al. [8] have also reported that the initial rewarding effects of cocaine are associated with an inhibition of LHb neurons and that the onset of the delayed anxiogenic response to the drug is directly associated with an increase in LHb activity and a resulting suppression of VTA DA neurons. When viewed in this context, the current findings suggest a role for 5-HT release within the LHb as a contributing factor to the LHb's modulation of the affective response to cocaine.
In addition to its role in regulating the VTA, the LHb is also one of the major inputs to the dorsal and median raphé 5-HT systems (see Metzger [27] for a recent review). While the LHb has been shown to receive reciprocal projections back from the DRN [62] we note that the bulk of 5-HT innervation targets the medial habenula (MHb) [27, [38] [39] [40] 63] . Analysis of mRNA transcripts in this region suggests that the 5-HT 1B receptor has an elevated expression in the LHb relative to the MHb [27, 39, 40] , which does support the hypothesis that the observed behavioral effects in this study were due primarily to modulation of the LHb, rather than MHb. However, due to the relatively small size and immediate adjacency of the LHb and MHb, it cannot be conclusively determined with any anatomical precision whether our manipulations produced their effects via modulation of the LHb, MHb, or both structures. Although most of the research in this area has focused on the LHb, the MHb has also been implicated in modulating the same affective states as the LHb, including drug withdrawal, depression, stress, and anxiety [64] . The MHb has also received a renewed interest for its role in nicotine addiction, due to the discovery that it contains a high concentration of nicotinic ACh receptors and has outputs to areas that regulate ACh release throughout the brain [64] . Clearly there is a need for more research on the MHb and its role in the behavioral effects of drugs of abuse.
5-HT itself appears to have mixed effects in the LHb. On post-synaptic LHb neurons, 5-HT produces primarily stimulatory effects via activation of 5-HT 2/3 receptors which enhance cellular depolarization [65, 66] . 5-HT can also act as an inhibitory signal through activation of inhibitory 5-HT 1B heteroreceptors located presynaptically on the glutamatergic inputs to the LHb [67, 68] . Additionally, local application of a 5-HT 1B agonist into the LHb has been shown to reduce 5-HT release as measured through microdialysis [69] . Thus, there are two possible mechanisms that could explain the results observed in this study. First, it could be that the 5-HT 1B agonist is reducing LHb activity indirectly via inhibition of glutamatergic inputs to the LHb; alternatively, these results could be explained by an inhibition of 5-HT release in the LHb via activation of the 5-HT 1B autoreceptors localized on the serotonergic fibers innervating this region. Preliminary studies in our lab are currently underway to address these two possibilities.
